Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Other Sep 23 | 2022New ADA/EASD 2022 T2DM Guidelines; EASD 2022 Key Press Releases (Sept 23)Purchase Blast
$599
Posted in: Basal Insulin, DPP-IVi, GLP-1RA + Basal, Other Sep 23 | 2022EASD 2022 Key Press Releases (Sept 22)Purchase Blast
$599
Posted in: GLP-1RA Sep 22 | 2022Pfizer to Advance Oral GLP-1RA Development; Pfizer EASD 2022 Investor CallPurchase Blast$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery Sep 21 | 2022Lilly’s Tempo Smart Button Receives 510(k) Clearance; EASD 2022 Key Press Releases (Sept 21)Purchase Blast$599
Posted in: Dual/triple agonist Sep 21 | 2022SURMOUNT-MMO Trial Design Presented at EASD 2022Purchase Blast$599
Posted in: Insulin Delivery, Other Sep 20 | 2022Insulet Omnipod 5 Receives CE Mark; Novo Nordisk and Octagon Therapeutics Collaboration for Inflammatory Disease Targets; Diamyd Presents Updated 12-month Results from Ph2 GADinLADA Trial; EASD 2022 Key Press Releases (Sept 20)Purchase Blast$599
Posted in: Insulin Delivery, Other Sep 19 | 2022Biocorp’s SoloSmart receives CE Mark; EASD 2022 Key Press Releases (Sept 19)Purchase Blast
$599
Posted in: Basal Insulin Sep 19 | 2022Tresiba AG vs. Basal Insulin Pricing AnalysisPurchase Blast
$599
Posted in: Other Sep 15 | 2022Alnylam and Regeneron to Advance NASH ALN-HSD AssetPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, Other Sep 13 | 2022Akero Becomes a Frontrunner in NASH; Lilly Initiates Tirzepatide Ph2 TREASURE-CKD Trial; Oramed’s Oral Insulin Ph2 NASH Topline ResultsPurchase Blast
$599
Posted in: Basal Insulin, Other Sep 12 | 2022Novo Partners with Microsoft for Drug Development; Novo Launches Unbranded Degludec; AZ Partners with Gatehouse Bio for HFpEF RNAi Therapeutic Development; September 2022 CHMP AgendaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Sep 08 | 2022FENIX Analysis: Mounjaro Launch UpdatePurchase Blast
$599
Posted in: Basal Insulin, Glucagon, Other Sep 08 | 2022Novo Licenses Zealand’s Zegalogue; Adocia Announces Preclinical PoC Data for its Islet Transplant; First Patient Dosed in G&L's QW Insulin Ph1 TrialPurchase Blast
$599
Posted in: Other Sep 06 | 2022Daprodustat FDA Adcom Scheduled for October 26, 2022Purchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Glucose Monitoring, Other Sep 02 | 2022Dexcom Promotes Jake Leach to COO; Biocon Receives More Form 483 Observations; Seraxis Appoints Paul Strumph as CMO; Intarcia ITCA-650 CRL Chronicle ConcludesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Other Sep 01 | 2022Ypsomed Launches Remote Bolus Feature; Lannett Completes Bs-glargine Pivotal Trial; Madrigal Initiates MAESTRO-NASH Outcomes Study for ResmetiromPurchase Blast
$599
Posted in: Other Aug 30 | 2022Repatha CVOT OLE Shows Long-term RRR; Poxel Announces Positive Results for PXL065 Ph2 Trial in NASHPurchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Other Aug 29 | 2022Thoughts on SURMOUNT-MMO after SELECT Interim AnalysisPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
